Array BioPharma Inc.

Array BioPharma Inc.

Array BioPharma Inc.

Overview
Date Founded

1998

Headquarters

3200 WALNUT STREET, BOULDER, CO, 80301

Type of Company

Public

Employees (Worldwide)

298

Industries

Pharmaceuticals
Biotechnology

Company Description

Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Contact Data
Trying to get in touch with decision makers at Array BioPharma Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Executive Officer

Chief Financial Officer & Chief Accounting Officer

Chief Operating Officer

Interim General Counsel

Chief Scientific Officer

Chief Medical Officer

Director-Corporate Communications & Investor

Senior Vice President, Human Resources

Board of Directors

Chairman at Humacyte, Inc.

Founder & General Partner at Boulder Ventures Ltd.

Paths to Array BioPharma Inc.
Potential Connections via
Relationship Science
You
Array BioPharma Inc.
Owners & Shareholders
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Point72 Asset Management is a research-driven investment management firm built around a core position in discretionary long/short equities, as well as systematic, global macro and other strategies. The firm seeks to achieve each Point72 Fund's investment objective by focusing primarily on long/short equity and systematic investment strategies and seeks to employ other investment strategies opportunistically. Point72 Asset Management employs these strategies in attempting to achieve an attractive return on capital consistent with principles that are designed to reduce the risk of permanent capital loss. The firm is an active investor and will use significant leverage, engages in short-sale transactions, and exercises various options and arbitrage strategies. In implementing specific strategies, Point72 Asset Management may manage assets such as equities (including listed, unlisted, traded or privately offered, domestic, foreign, depository receipts and preferred); secured and unsecured debt (including both corporate and sovereign, mortgage-backed to-be-announced securities, bank loans, loans originated by a Point72 Fund, vendor claims and other legal and/or contractual claims); futures; forward contracts; options; convertible bonds and preferred stock; derivative instruments, including listed and over-the-counter, swaps and other equity or fixed income related instruments; contracts for differences; currencies; and commodities.

Details Hidden

FCM invest globally across asset classes that seek to achieve superior risk-adjusted returns through a process of bottom-up fundamental analysis that emphasizes capital preservation. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Recent Transactions
Details Hidden

Pfizer, Inc. purchases Array BioPharma Inc.

Details Hidden

Array BioPharma Inc. issued . USD Common Stock

Details Hidden

Array BioPharma Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onArray BioPharma Inc. issued . USD Common Stock

Escrow Agent

Advised onArray BioPharma Inc. issued . USD Common Stock

Underwriter

Advised onArray BioPharma Inc. issued . USD Common Stock

Legal Advisor

Advised onArray BioPharma Inc. issued . USD Common Stock

Underwriter

Advised onArray BioPharma Inc. issued . USD Common Stock

Managing Director

Advised onArray BioPharma Inc. issued Common Stock

Advisors & Consultants
Advisor

Chief Financial Officer at Clinone, Inc.

Consultant

Co-Founder at Array BioPharma Inc.

Advisor

Secretary & General Counsel at Peloton Therapeutics, Inc.

Clients

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Key Stats and Financials As of 2018
Market Capitalization
$4.83B
Total Enterprise Value
$3.03B
Earnings Per Share
$-0.74
Revenue
$174M
Enterprise Value Sales
17.44x
TEVNet Income
-20.56x
Debt TEV
0.04x
Total Debt
$112M
Total Equity
$220M
Net Profit
$-147M
EBITDAMargin
-73.48%
EBITDA
$-128M
Three Year Compounded Annual Growth Rate Of Revenue
49.59%
Five Year Compounded Annual Growth Rate Of Revenue
20.09%
Investments
Details Hidden

Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.

Investors
Details Hidden

Venture Partner at OrbiMed Advisors LLC

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Co-Founder at Chemizon, Inc.

Suppliers
Foundation Medicine, Inc. Medical Support Services | CAMBRIDGE, MA

Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. Its products includes: FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers; FoundationACT; and FoundationFocus CDxBRCA. The company was founded by Alexis Borisy in November 2009 and is headquartered in Cambridge, MA.

Medidata Solutions, Inc. Pension Funds & Sovereign Wealth | NEW YORK, NY

Welcome to Medidata Solutions. We recognize that our customers' life science research fosters the critically important goals of bringing life-saving and life-enhancing treatments to the public, and we are proud to support this work. Medidata is committed to providing clinical research organizations with the most advanced tools for planning and managing their clinical trials. Our mission is to put innovative technology and insightful data into researchers' hands to help bring treatments to market as safely, efficiently and effectively as possible. The Medidata team has looked at all steps of the clinical trial process—spanning operational and clinical activities—and created solutions for companies of all sizes that use cutting-edge technology, process change management and implementation planning, and robust databases and analytics to take risk, time and resources out of the trial process. By focusing on critical decision-points in clinical research, we are working to develop solutions that provide all members of the research team with novel analytic tools and information technology to maximize their clinical investments

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Array BioPharma Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Array BioPharma Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Array BioPharma Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/array-biopharma-inc-53881
  • https://relationshipscience.com/organization/array-biopharma-inc-53881